Iterum Therapeutics's top three insider shareholders as of September 17, 2026 are Ronald Hunt (Director, 345.02K shares), Michael W. Dunne (Chief Scientific Officer, 241.00K shares), Corey N. Fishman (Chief Executive Officer, 137.06K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ronald Hunt | Director | 0 | 345,020 | 345,020 | 44.3% | 12 Aug, 2024 |
| 2 | Michael W. Dunne | Chief Scientific Officer | 241,001 | 0 | 241,001 | 30.9% | 20 Nov, 2025 |
| 3 | Corey N. Fishman | Chief Executive Officer | 137,062 | 0 | 137,062 | 17.6% | 12 Aug, 2024 |
| 4 | Beth Hecht | Director | 18,839 | 0 | 18,839 | 2.4% | 15 Jun, 2023 |
| 5 | Mark Chin | Director | 18,306 | 0 | 18,306 | 2.4% | 15 Jun, 2023 |
| 6 | Sailaja Puttagunta | Chief Medical Officer | 10,369 | 0 | 10,369 | 1.3% | 04 Dec, 2023 |
| 7 | Judith M. Matthews | Chief Financial Officer | 8,135 | 0 | 8,135 | 1.0% | 14 Mar, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 18 Nov, 2025 | Michael W. Dunne | Director | Acquired P | 6,000 | $0.37 | $2.19K | 241,001 | Direct |
| 08 Aug, 2025 | Michael W. Dunne | Director | Acquired P | 15,000 | $0.72 | $10.85K | 235,001 | Direct |
| 01 Jul, 2025 | Christine Coyne | Chief Commercial Officer | Acquired A | 200,000 | $0.00 | $0 | 200,000 | Direct |
| 06 Aug, 2024 | Corey N. Fishman | Chief Executive Officer | Acquired M | 82,613 | — | — | 137,062 | Direct |
| 06 Aug, 2024 | Ronald Hunt | Director | Acquired M | 182,453 | — | — | 253,898 | Indirect |
| 06 Aug, 2024 | Michael W. Dunne | Director | Acquired M | 106,247 | — | — | 220,001 | Direct |
| 06 Aug, 2024 | Michael W. Dunne | Director | Disposed M | 212,494 | $0.00 | $0 | 0 | Direct |
| 06 Aug, 2024 | Ronald Hunt | Director | Acquired M | 65,481 | — | — | 91,122 | Indirect |
| 06 Aug, 2024 | Corey N. Fishman | Chief Executive Officer | Disposed M | 165,226 | $0.00 | $0 | 0 | Direct |
| 06 Aug, 2024 | Michael W. Dunne | Director | Acquired M | 106,247 | — | — | 106,247 | Direct |
| 06 Aug, 2024 | Ronald Hunt | Director | Disposed M | 364,906 | $0.00 | $0 | 0 | Indirect |
| 06 Aug, 2024 | Corey N. Fishman | Chief Executive Officer | Acquired M | 82,613 | — | — | 82,613 | Direct |
| 06 Aug, 2024 | Ronald Hunt | Director | Acquired M | 182,453 | — | — | 182,453 | Indirect |
| 06 Aug, 2024 | Michael W. Dunne | Director | Acquired M | 106,247 | — | — | 106,247 | Direct |
| 06 Aug, 2024 | Corey N. Fishman | Chief Executive Officer | Acquired M | 82,613 | — | — | 82,613 | Direct |
| 06 Aug, 2024 | Ronald Hunt | Director | Acquired M | 182,453 | — | — | 182,453 | Indirect |
| 06 Aug, 2024 | Ronald Hunt | Director | Disposed M | 130,962 | $0.00 | $0 | 0 | Indirect |
| 06 Aug, 2024 | Ronald Hunt | Director | Acquired M | 65,481 | — | — | 65,481 | Indirect |
| 06 Aug, 2024 | Ronald Hunt | Director | Acquired M | 65,481 | — | — | 65,481 | Indirect |
| 22 Dec, 2023 | Michael W. Dunne | Director | Acquired P | 25,000 | $1.40 | $35.00K | 113,754 | Direct |